Comparison of intranasal steroid application using nasal spray and spray-sol to treat allergic rhinitis: a preliminary investigation

Allergic Rhinitis (AR) is a chronic inflammatory disease of sino-nasal mucosa, is IgE-mediated, and affects 10-40% of the global population. This study aimed to compare the efficacy of nasal administration of Beclomethasone Dipropionate (BDP) delivered via Spray-sol with nasal spray in patients suff...

ver descrição completa

Detalhes bibliográficos
Autores: Moffa, A. (Antonio)|||/items/bbc3994a-d395-46bc-a2d7-55fc4e5c7ebc, Giorgi, L. (Lucrezia)|||/items/c816220d-048a-4d62-a3aa-96942e1a8206, Carnuccio, L. (Luca)|||/items/9f29a2aa-1e08-4cda-b3cd-95017a14baf4, Lugo, R. (Rodolfo)|||/items/7ed02dd5-47b3-49a6-bbe8-6ebb30c2a148, Casale-Falcone, M. (Manuele)|||/items/53a70511-8d7b-4e1b-9298-004cf6e6b843, Baptista-Jardin, P.M. (Peter Michael)|||/items/66ecbc41-d708-4b43-a527-b733813d5195
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/67254
Acesso em linha:https://hdl.handle.net/10171/67254
Access Level:acceso abierto
Palavra-chave:Impact
Spray-sol
Nasal device
Nasal spray
Beclomethasone dipropionate
Allergic rhinitis
Potential role
Delivery
Ectoine
Descrição
Resumo:Allergic Rhinitis (AR) is a chronic inflammatory disease of sino-nasal mucosa, is IgE-mediated, and affects 10-40% of the global population. This study aimed to compare the efficacy of nasal administration of Beclomethasone Dipropionate (BDP) delivered via Spray-sol with nasal spray in patients suffering from AR. We included 28 AR patients assigned to one of the two following treatments: the Spray-sol group (BDP via Spray-sol) (n = 13) and the spray group (BDP using a common nasal spray) (n = 15). Both treatments were administered twice daily for 4 weeks. A nasal endoscopy evaluation and Total Nasal Symptom Score were performed at baseline and after treatment. The Spray-sol group showed better results than the spray group regarding nasal endoscopy (edema, p < 0.01; irritation, p < 0.01; secretion, p < 0.01) and nasal symptoms (nasal congestion, p < 0.05; rhinorrhea, p < 0.05; sneezing, p < 0.05; and total score, p < 0.05). No side effects were recorded. These data supported the fact that the use of BDP delivered with Spray-sol is more effective than BDP nasal spray in AR patients. Further studies are needed to confirm these encouraging results.

Registos relacionados